Sign In
Buy AMRN
$14.53
+0.0600 (+0.415%)
At Close: Jun 03, 2026
New Strong Sell Stocks for January 28th
06:41am, Wednesday, 28'th Jan 2026
AMRN, AMTB and AAWH have been added to the Zacks Rank #5 (Strong Sell) List on January 28th, 2026.
US Supreme Court to hear 'skinny label' patent fight involving Amarin
02:44pm, Friday, 16'th Jan 2026
The U.S. Supreme Court agreed on Friday to hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa that could have broad consequences for generic drug makers and so-called "skinny
AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations
12:50pm, Friday, 09'th Jan 2026
AMRN jumps 17% after Q4 and FY2025 preliminary sales beat expectations. The release also reflected positive Q4 cash flow and progress on cost cuts.
DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on rece
Amarin (NASDAQ:AMRN) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened
03:08am, Friday, 09'th Jan 2026
Amarin Corporation PLC (NASDAQ: AMRN - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $15.89 and traded a
Amarin Corporation PLC $AMRN Stock Holdings Decreased by Acadian Asset Management LLC
03:16am, Friday, 14'th Nov 2025
Acadian Asset Management LLC trimmed its position in Amarin Corporation PLC (NASDAQ: AMRN) by 93.6% in the second quarter, according to its most recent disclosure with the SEC. The institutional inves
DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new pos
DUBLIN and BRIDGEWATER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be p
Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down
01:11pm, Thursday, 30'th Oct 2025
AMRN's third-quarter earnings fall short of expectations, but stronger U.S. Vascepa sales push revenues above estimates.
Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript
10:21am, Wednesday, 29'th Oct 2025
Amarin Corporation plc ( AMRN ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Aaron Berg - CEO, President & Director Peter Fishman - Senior VP & CFO Conference Call Participa
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
08:00am, Tuesday, 14'th Oct 2025
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, in collaboration wi
Amarin (AMRN) Surges 12.5%: Is This an Indication of Further Gains?
10:46am, Monday, 06'th Oct 2025
Amarin (AMRN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Amarin: Vascepa's Global Pivot From U.S. Squeeze To International Boom
05:52pm, Monday, 29'th Sep 2025
Amarin (AMRN) is transforming Vascepa from a declining U.S. business into a global cardiovascular growth story, driven by disciplined expense control and strategic partnerships. AMRN's European and Re
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
08:30am, Sunday, 31'st Aug 2025
-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action -- -- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action --
-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or Very High-Risk Patients Based on REDUCE-IT -- DUBLIN and BRID
